首页 > 新闻 > 正文

倚天屠龙记之魔教教主

Pfizer cuts full-year outlook due to declining sales of Covid-19-related products_我的网站

追梦赤子心

一 | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。俳優の今井翼（44）が24日までにインスタグラムを更新。細マッチョの激変ボディを公開し、話題になっている。■【画像】「なにこのムキムキ感」“渋おじ化”で話題の今井翼、ふっくら→細マッチョの激変ボディ　この日、今井は《今日も元気にトレーニング!!》とつづり、ジムで撮影したショットを投稿。写真の今井はタンクトップ＆パンツ姿で、ムキムキの上腕二頭筋が目立っている。

二 | 「10代の頃から芸能界で活躍し、2002年に『タッキー＆翼』として本格的にデビューした今井さん。

三 | その後も舞台やテレビドラマ、映画で活躍してきましたが、2014年にメニエール病を発症して以降、表舞台から退いていた時期も。　2020年に舞台で復帰し、昨年10月2日放送のバラエティ番組『秘密のケンミンSHOW極』（日本テレビ系）に出演時には、以前のイメージと比べるとややふっくらした印象となり、口ヒゲとあごヒゲを生やした姿が“渋おじ”と話題になりました。　今回公開されたジムでのショットは、『秘密のケンミンSHOW極』出演時よりシュッとしたようにも見え、鍛え抜かれた肉体が見事です。かつての『タッキー＆翼』時代とは全く違った、渋めのワイルド路線も魅力的ですね」（女性誌ライター）　今井のたくましいタンクトップ姿に、ファンからは《よい身体になりましたね》《ガタイがよくなってる　すごいです　かっこいい》《上半身が凄い　肩から腕、見えないけど胸板も凄いんだろうな》《素敵な肉体美　カッコ良すぎます》《段々若返ってますねー。